Sandoz Biosimilar Portfolio and Pipeline [1]

Sandoz, a Novartis division, has a leading biosimilar portfolio and leading pipeline in immunology, oncology and endocrinology.

Tab:

**Portfolio [2]**

<table>
<thead>
<tr>
<th>Sandoz biosimilar</th>
<th>Indication area</th>
</tr>
</thead>
<tbody>
<tr>
<td>Omnitrope® [somatropin]</td>
<td>Endocrinology</td>
</tr>
<tr>
<td>Erelzi® [etanercept]</td>
<td>Immunology (rheumatology, dermatology)</td>
</tr>
<tr>
<td>Binocrit® [epoetin alfa]</td>
<td>Oncology (supportive cancer care)</td>
</tr>
<tr>
<td>Zarzio®/ Zarxio® [filgrastim]</td>
<td>Oncology (supportive cancer care)</td>
</tr>
<tr>
<td>Ziextenzo® [pegfilgrastim]</td>
<td>Oncology (supportive cancer care)</td>
</tr>
<tr>
<td>Rixathon® [rituximab]</td>
<td>Oncology (blood cancers), Immunology (rheumatology)</td>
</tr>
<tr>
<td>Hyrimoz® [adalimumab]</td>
<td>Immunology (rheumatology, gastroenterology, dermatology)</td>
</tr>
<tr>
<td>Zessly® [infliximab]</td>
<td>Immunology (rheumatology, gastroenterology, dermatology)</td>
</tr>
</tbody>
</table>


**Immunology [3]**

Immune system disorders affect hundreds of millions of people worldwide and can severely impact quality of life and even life expectancy1,2,3. These debilitating disorders include those affecting the joints (such as rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis), the skin (such as psoriasis) and the gut (such as Crohn’s disease and ulcerative colitis).
Sandoz is the long-term partner supporting rheumatologists, dermatologists and gastroenterologists in advancing patient care without compromise. Our proven expertise and experience in biosimilars, provides high-quality affordable medicines in this therapy area.

We are committed to providing life-changing immunology therapies and have a robust biosimilar immunology portfolio with Erelzi®⁴, Hyrimoz®⁵, Zessly®⁶ and Rixathon®⁷ already marketed in Europe.

Learn more about the wider Novartis Group’s involvement in immunology [⁴]


Oncology [¹⁰]

Cancer is one of the leading causes of death and places a significant and growing burden on healthcare systems around the world¹.

Sandoz is committed to increasing physician and patient access to broader options for quality cancer treatments that make up the foundation of cancer care. Biosimilar treatment options could free up resources, which can be redeployed for innovation, access and new interventions within healthcare systems to support and manage the burden of oncology care.

We currently market Zarzio®² / Zarxio®², Binocrit®³ and Ziextenzo®⁴, used in supportive cancer care and Rixathon®⁵ to treat blood cancers. Sandoz also has a robust portfolio of investigational oncology biosimilars it is bringing to market in the future.

In addition to biosimilars, Sandoz oncology medicines have a presence in more than 93
countries and provide therapy options across the 10 most prevalent tumor types including Breast cancer, Prostate cancer, Colorectal cancer, Lung cancer, Blood cancer.

With a leading global generic oncology portfolio of >50 products, from chemotherapy, via hormones and supportive care to targeted therapies, Sandoz has been manufacturing oncology treatments for over 30 years, with a strong focus on delivering medicines of the highest purity and quality and expanding our portfolio to ensure we continue to provide a comprehensive range of oncology products.

Sandoz is committed to playing a key role in achieving global healthcare goals, by pioneering new approaches to drive increased access to healthcare worldwide.

Beyond providing high-quality affordable medicines, Sandoz is also committed to improve health care infrastructures worldwide through various partnerships and dedicated teams in many countries interacting daily with health care practitioners, providers, payers and patients.

Learn more about Novartis in oncology [11]


Accordion Type: Collapsible

Source URL: https://www.sandoz.com/our-work/biopharmaceuticals/sandoz-biosimilar-portfolio-and-pipeline

Links